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Abstract
Antibiotic resistance is a serious public health threat, primarily, resulting from the excess
and inappropriate use of antibiotics. Antibiotic resistance and antibiotic consumption trends may
differ along the U.S-Mexico border from the rest of the U.S. due to geographical and cultural
differences unique to the border region. The objectives of this study were: 1.) To examine the
trends in antibiotic resistance among E. coli, ESBL producing E. coli, P. aeruginosa, S. aureus,
and MRSA over a 3-year period (2013, 2014, 2015) in a U.S.-Mexico border area hospital; 2.) To
examine the trends in antibiotic consumption among aztreonam, cefazolin, cefepime, ceftriaxone,
ciprofloxacin, gentamicin, and levofloxacin over a 3-year period (2013, 2014, 2015) in a U.S.Mexico border area hospital; 3.) To determine if a correlation exists between the consumption of
these antibiotics and antibiotic resistance trends seen in a U.S.-Mexico border area hospital. This
study employed a retrospective analysis of antibiotic resistance and antibiotic consumption data in
a small border area hospital in El Paso, Texas to determine if a correlation existed between the two
variables for the time-period of 2013-2015. The results of this study identified statistically
significant increases in resistance for E. coli to aztreonam (p-value <0.0001), cefazolin (p-value
<0.0001), cefepime (p-value <0.0001), ceftriaxone (p-value <0.0001), and ciprofloxacin (p-value
0.001). A statistically significant increase in resistance for MRSA to gentamicin was also
identified (p-value 0.044). Statistically significant decreases in resistance were identified for
ESBL producing E. coli to gentamicin (p-value 0.002) and for S. aureus to the following
antibiotics: ciprofloxacin (p-value 0.023), levofloxacin (p-value 0.018), and penicillin (p-value
0.021). No correlations were identified between any of the susceptibilities of the bacterial species
and the antibiotic consumption data analyzed.
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Chapter 1: Introduction
The discovery of antibiotics has been one of the world’s most revolutionizing discoveries
of the modern era. Since the discovery of penicillin in the late 1920s, antibiotics have saved
millions of lives (Centers for Disease Control and Prevention, 2013) through curing, previously,
incurable illnesses. In addition, antibiotics have played a significant role in the prevention of
surgical site infections when distributed as a prophylactic (McHugh, Collins, Corrigan, Hill, &
Humphreys, 2011). Despite the advances antibiotics have made in improving the lives of millions
of people, they have also, paradoxically, indirectly contributed to the mortality and morbidity of
hundreds of thousands of lives.
Antibiotic resistance is a serious public health threat throughout the globe. Antibiotic
resistance occurs when bacteria are able to survive in the presence of antibiotics without effect.
Antibiotic resistance can be innate or acquired. With innate resistance, all strains of a bacterial
species are naturally resistant to a class of antibiotics (Tenover, 2006). Acquired resistance occurs
when bacteria become less susceptible to antibiotics that were once effective against them through
the selective pressures of antibiotic use (Tenover, 2006). This differs from innate resistance in
that acquired resistance traits are only found in some strains or subpopulations of a bacterial
species (Michigan State University, 2011).
There is limited data on antibiotic resistance and antibiotic consumption along the U.S.Mexico border. Due to various geographical and cultural differences that are unique to the U.S.Mexico border region and population, antibiotic resistance and consumption trends may differ
from those of the rest of the U.S. It is therefore essential to track antibiotic resistance and antibiotic
consumption in this unique region.
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Chapter 2: Background and Significance
Mechanisms of antibiotic resistance
There are four main antibiotic resistance mechanisms by which bacteria resist the effects
of antibiotics (Figure 1). The first mechanism involves preventing antibiotic access to its target
by reducing its ability to penetrate a cell (Michigan State University, 2011). In this mechanism,
changes in the outer membrane permeability of a bacterial cell occur, such as lacking the
expression of a porin protein needed for antibiotic entry into the cell. Imipenem resistant P.
aeruginosa, as an example, lacks the OprD porin required for entry of this antibiotic into the cell
(Cloete, 2003). The second mechanism involves the acquisition of general or specific efflux
pumps to expel antibiotics from the cell (Michigan State University, 2011). This mechanism
prevents antibiotics from reaching the intracellular concentrations needed to have an effect on the
bacterial cell (Michigan State University, 2011).

Efflux pumps contribute significantly to

multidrug resistance as most efflux pumps are multidrug pumps capable of expelling a variety of
antibiotic classes from the cell (Giedraitiene, Vitkauskiene, Naginiene, & Pavilonis, 2011). The
MepA efflux pump of S. aureus, as an example, is responsible for resistance to tigecycline,
minocycline,

tetracycline,

ciprofloxacin,

norfloxacin,

ethidium

bromide,

and

tetraphenylphosphonium bromide (Giedraitiene et al., 2011). The third mechanism involves
inactivating the antibiotic through modification (Michigan State University, 2011). A common
mode of inactivation occurs through the use of enzymes. Extended-spectrum beta-lactamases
(ESBL) are enzymes that hydrolyze beta-lactam antibiotics rendering them ineffective. Extendedspectrum beta-lactamases are capable of inactivating penicillins; first, second, and third generation
cephalosporins, and aztreonam, however, they do not have an effect on the cephamycins or
carbapenems (Rawat & Nair, 2010). Extended-spectrum beta-lactamase producing E. coli is a
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serious health threat and a common cause of hospital acquired infections. The fourth resistance
mechanism involves modifying the antibiotic target site within the bacterial cell (Michigan State
University, 2011). Penicillin binding proteins (PBPs), as an example, are the target site for betalactam antibiotics. The acquisition of altered PBPs in S. aureus (PBP2a) demonstrates reduced
affinity for beta-lactam antibiotics and allows cell wall synthesis to occur even in the presence of
normally lethal concentrations of beta-lactam antibiotics (Lim & Strynadka, 2002). All of these
mechanisms of resistance are obtained genetically either through random mutation as seen with
innate resistance, or through horizontal gene transfer associated with acquired resistance.
Horizontal gene transfer occurs via transformation, transduction, or conjugation.
Transformation involves the uptake of naked deoxyribonucleic acid (DNA) that has been released
by bacteria into the environment after cell lysis and the incorporation of the resistant genes into
the host’s genome (Tenover, 2006). Transduction involves the transfer of resistant genes from one
bacterium to another by bacteriophages (Tenover, 2006). Conjugation involves the transfer of
resistant genes from cell-to-cell contact via the pilus (Michigan State University, 2011). In all
cases of acquired resistance, the selective pressure of antibiotic use leads to the acquisition of
resistant genes and the proliferation of resistant bacteria.
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Figure 1: Mechanisms of Antibiotic Resistance. Reprinted with permission from J. O. Rivera,
2018.
Excess use of antibiotics
Selective pressures such as the inappropriate and excess use of antibiotics in a hospital and
outpatient setting are believed to be the major facilitators of the growing resistance trend (Canton,
Horcajada, Oliver, Garbajosa, & Vila, 2013; Fleming-Dutra et al., 2016). Globally, antibiotic use
has increased by 36% between the years 2000 and 2010 with a large absolute increase in
consumption seen with the cephalosporins, broad-spectrum penicillins, and fluoroquinolones (Van
Boeckel et al., 2015). Total antibiotic use in the U.S. hospital setting has not changed significantly
during the last decade, however, the use of broad spectrum antibiotics has increased significantly
(Baggs, Fridkin, Pollack, Srinivasan, & Jernigan, 2016). Similar findings are observed when
examining U.S. outpatient antibiotic use. In concordance with antibiotic use in a hospital setting,
broad spectrum antibiotic use has also increased significantly in the outpatient setting (Lee et al.,
2014). Estimates of inappropriate antibiotic use varies globally. Overall, global estimates of
4

inappropriate antibiotic use ranges from 30% up to 81% (Fleming-Dutra et al., 2016; Hatam,
Askarian, Moravveji, & Assadian, 2011; Ingram, Seet, Budgeon, & Murray, 2012). Recent studies
documenting inappropriate antibiotic use in the U.S. hospital setting are rare. It has been well
accepted, however, that up to 50% of antibiotics prescribed in the U.S. hospital setting are
inappropriate (Dellit et al., 2007; Hecker, Aron, Patel, Lehmann, & Donskey, 2003). Hecker et al.
in 2003 estimated that 28% of antibiotic use in a U.S. hospital setting were inappropriate (Hecker
et al., 2003). This estimate correlates well with a recent study demonstrating that 30% of antibiotic
use in the U.S. outpatient setting is inappropriate (Fleming-Dutra et al., 2016). Contributing to the
excess use of antibiotics are various factors such as physician response to patient pressures,
diagnostic uncertainty among physicians, and self-medication among the general population.
Physician response to patient pressures in prescribing antibiotics are evident in the
outpatient setting. Qualitative studies have identified patient pressure as a major barrier to the
judicious use of antibiotics (Dempsey, Businger, Whaley, Gagne, & Linder, 2014; Szymczak,
Feemster, Zaoutis, & Gerber, 2014). Patient expectation of antibiotic prescriptions is perceived as
a general norm among physicians and studies have indicated that physicians sometimes submit to
these expectations to appease patients (Szymczak et al., 2014). Additionally, studies have
identified that physicians also feel that time constraints are a barrier to resolving patient
misconceptions regarding antibiotic use. Physicians may be compelled to prescribe antibiotics as
opposed to educating patients on appropriate use in order to end patient visits quicker and increase
financial productivity (Dempsey et al., 2014). Diagnostic uncertainty also contributes to the over
prescription of antibiotics. Qualitative studies have indicated that diagnostic uncertainty is a
concern among physicians and can lead to prescribing antibiotics to avoid undertreating an
infection (Dempsey et al., 2014; May et al., 2014). This concern highlights the need for improved
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rapid and accurate point-of-care diagnostic tests. Non-prescription use or self-medication is
another contributor to the excess use of antibiotics. The prevalence of non-prescription antibiotic
use varies among different populations. Past studies have documented non-prescription antibiotic
use primarily among Latin American immigrants (Zoorob, Grigoryan, Nash, & Trautner, 2016).
The prevalence of non-prescription antibiotic use among this population ranges from 19-26%
(Zoorob et al., 2016). In another study, the prevalence of non-prescription antibiotic use among a
diverse population group in the state of Texas in the U.S. was lower (5%) (Zoorob et al., 2016).
In this study, however, 25.4% of respondents indicated willingness to use antibiotics without a
prescription and 14.2% indicated they had antibiotics stored at home (Zoorob et al., 2016). In both
studies, the most common indications for non-prescription antibiotic use was for symptoms of
upper respiratory illnesses, which are most likely caused by viruses.
Antibiotics are also commonly used in food animals. Previous data documents that 16%
of all lactating cows in the U.S. receive therapeutic antibiotics for mastitis annually and
approximately 100% of lactating cows receive prophylactic antibiotics after each lactation
(Landers, Cohen, Wittum, & Larson, 2012). Additionally, 42% of beef calves and 88% of swine
for food consumption receive prophylactic antibiotics (Landers et al., 2012). Antibiotic
consumption in food animals varies with past estimates of total antibiotic use in the U.S. as high
as 24.6 million pounds attributed to animal prophylactic use compared to 3 million pounds for
human use (Landers et al., 2012). Many of the prophylactic antibiotics used in animals are also
used to treat human disease such as tetracyclines, penicillins, and sulfonamides (Landers et al.,
2012). The consequences of antibiotic use in animals and subsequently humans are both direct
and indirect. Increased risk of resistant colonization or infection in humans results from farm
animal exposure to antibiotic treated animals (Landers et al., 2012). Outbreaks of diarrheal disease
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can result from the consumption of food contaminated with antibiotic-resistant bacteria (Landers
et al., 2012). Antibiotic contaminated meat products can also stimulate resistance in the gut
microbiome through consumption (Landers et al., 2012). Indirectly, antibiotic-resistant bacteria
in animals can spread to humans through animal transport, from animal waste contaminating the
water supply and through contact with pet animals exposed to antibiotic-resistant-containing pet
food (Landers et al., 2012).
Consequences of excess antibiotic use
Antibiotics are not without their side effects and inappropriate and excess use puts
individuals at risk of developing resistant infections or other adverse events. It is estimated that 2
million people a year in the U.S. develop serious bacterial infections with bacteria that is resistant
to at least one of the antibiotics designed to target the bacteria (Centers for Disease Control and
Prevention, 2013). Mortality related to these infections is estimated at 23,000 deaths a year
(Centers for Disease Control and Prevention, 2013). In addition to these infections approximately
250,000 people yearly require care for Clostridium difficile infections (CDI) which largely occurs
as a result of antibiotic use leading to a disruption of the gut microbiome (Centers for Disease
Control and Prevention, 2013). Several antibiotic resistance patterns have emerged since the
introduction of antibiotics, however, antibiotic resistance patterns among gram-negative bacteria
are a main concern. Gram-negative bacteria are becoming resistant to almost all antibiotics used
to treat these pathogens (Centers for Disease Control and Prevention, 2013). Additionally,
mortality rates among hospitalized patients with multidrug-resistant gram-negative bacteria ranges
from 30-70% (Tamma, Cosgrove, & Maragakis, 2012). Carbapenem-resistant Enterobacteriaceae
(CRE) is a current urgent public health threat. It is estimated that 140,000 healthcare-associated
Enterobacteriaceae infections occur in the U.S. annually and approximately 9,300 are caused by
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CRE (Centers for Disease Control and Prevention, 2013). Up to half of blood stream infections
caused by CRE result in death (Centers for Disease Control and Prevention, 2013). Extendedspectrum beta-lactamase producing Enterobacteriaceae and multidrug-resistant P. aeruginosa are
responsible for a combined 32,000 and 2,100 annual healthcare-associated infections and deaths
respectively (Centers for Disease Control and Prevention, 2013). Among gram-positive bacteria,
methicillin-resistant S. aureus (MRSA) is a serious public health threat as this species is the leading
cause of healthcare-associated infections in the U.S. (Centers for Disease Control and Prevention,
2013). Methicillin-resistant S. aureus is often multidrug-resistant and accounts for approximately
80,461 severe infections and about 11,285 deaths per year (Centers for Disease Control and
Prevention, 2013). Total attributable societal and medical costs for antibiotic resistant infections
is difficult to calculate but has been estimated as high as 55 billion dollars a year (2008 dollars)
(Centers for Disease Control and Prevention, 2013).
Mitigation of antibiotic resistance
The medical and economic consequences of antibiotic resistance can be mitigated,
however, through the prudent use of antibiotics such as with the implementation of antimicrobial
stewardship programs (ASPs). Antimicrobial stewardship programs serve as a tool to combat
antibiotic resistance. Antimicrobial stewardship programs aim to reduce the inappropriate use of
antibiotics through various interventions designed to promote the judicious use of antibiotics. An
increasing body of evidence exists supporting the use of these programs. These programs can
optimize the treatment of infections while reducing a number of adverse events associated with
antibiotic use such as: reducing treatment failures, reducing the incidence of CDI, and reducing
the incidence of antibiotic resistant infections (Centers for Disease Control and Prevention, 2014).
In response to the evidence of the benefits of ASPs, the Centers for Disease Control and Prevention
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(CDC) now recommends that all acute care hospitals implement ASPs in an effort to quell
antibiotic resistance and improve patient outcomes. Hospital antimicrobial stewardship programs
have been shown to decrease resistance among many pathogens of clinical relevance (Kaki et al.,
2011). Additionally, hospital ASPs have also demonstrated other favorable outcomes such as
reducing the incidence of CDI, and hospital-associated vancomycin-resistant enterococci
infections (Nowak, Nelson, Breidenbach, Thompson, & Carson, 2012; Wenisch et al., 2014).
Although data on outpatient ASPs is limited, Dantes et al. (2015) estimated that a reduction of
outpatient antibiotic prescribing rates by 10% would lead to a 16.8% overall decrease in
community-associated CDI rates (Dantes et al., 2015). This indicates that outpatient ASPs may
be helpful to mitigate the adverse effects associated with inappropriate antibiotic use.
U.S.-Mexico border region
The U.S.- Mexico border is roughly 2000 miles long and spans 62.5 miles to the south and
north of the international border and across four U.S. and six Mexican states. The U.S.-Mexico
border is a unique geographical and cultural setting with a large bi-national population and
approximately 200 million passenger and pedestrian crossings in 2016 (Bureau of Transportation
Statistics, 2017). Additionally, highly impoverished settlements, known as “colonias,” are present
in the border region and it is estimated that approximately 400,000 inhabitants occupy these
“colonias” (Mier et al., 2008). In general, approximately 25% of U.S. border residents live below
the federal poverty level compared to 15% for the entire U.S. (The AIDS Education and Training
Center, 2014). Border residents face unique challenges in relation to healthcare. The Texas border
region, for example, has poverty rates that are approximately 14% higher than the rest of the U.S.
(Texas Department of State Health Services, 2013). Additionally, there are high rates of uninsured
among Texas border residents. Among Texas border residents, the rate of uninsured was 34.0%
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compared to 14.5% for the entire U.S. in 2013 (Barnett & Berchick, 2017; Texas Department of
State Health Services, 2013). The Texas border region is also a medically underserved area with
only six public health departments serving the 32 border counties in Texas and over half of the
border counties have no hospital (The AIDS Education and Training Center, 2014). In El Paso,
Texas, the poverty rate is at approximately 23% (Texas Department of State Health Services, 2013)
and approximately 30% of residents are uninsured (Texas Medical Association, 2017). Factors
such as poverty and the lack of health insurance have forced border residents to utilize healthcare
services across the border in Mexico. One study estimated healthcare utilization in Mexico among
Texas border residents at 49% for the purchasing of medicines and approximately 37% for
physician visits (Su, Pratt, Stimpson, Wong, & Pagán, 2014).
Surveillance data on antimicrobial resistance and consumption is limited in the U.S.Mexico border region. Due to differences in the accessibility of antibiotics in Mexico, overuse
leading to increased antibiotic resistance is a major concern among border communities (Homedes
& Ugalde, 2012). One study, conducted on a convenience sample of Mexican pharmacies,
documented 83% of antibiotics purchased by U.S. residents from Mexican pharmacies were
purchased without a prescription and were self-prescribed (Homedes & Ugalde, 2012). This same
study also documented several concerning pharmacy practices in Mexico. Among U.S. and
Mexican residents who purchased antibiotics from Mexican pharmacies during this study period,
57% purchased antibiotics without a prescription as recommended by the pharmacy clerk
(Homedes & Ugalde, 2012). Additionally, 82% of these clerks only achieved a secondary
education and their training and knowledge of medications comes largely from pharmaceutical
representatives (Homedes & Ugalde, 2012). Although published antibiotic resistance data in the
border region is rare, one study documented a higher prevalence of MRSA in El Paso, Texas when
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compared to its Mexican counterpart, Ciudad Juarez (Rivera et al., 2009). Another study
documented statistically significant increasing trends in resistance among quinolone-resistant P.
aeruginosa, quinolone-resistant E. coli and MRSA among U.S. hospitals on the Mexican border
(Benoit, Ellingson, Waterman, & Pearson, 2014). Other differences in antibiotic resistance trends
may also exist, however, without increased knowledge on this subject matter, these findings may
remain hidden.
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Chapter 3: Goals and Objectives
The main goal of this study is to increase knowledge of antibiotic resistance and antibiotic
consumption trends in the U.S.-Mexico border region. The three major objectives of this study
are; 1.) To examine the trends in antibiotic resistance among E. coli, ESBL producing E. coli, P.
aeruginosa, S. aureus, and MRSA over a 3-year period (2013, 2014, 2015) in a U.S.-Mexico
border area hospital; 2.) To examine the trends in antibiotic consumption among aztreonam,
cefazolin, cefepime, ceftriaxone, ciprofloxacin, gentamicin, and levofloxacin over a 3-year period
(2013, 2014, 2015) in a U.S.-Mexico border area hospital; 3.) To determine if a correlation exists
between the consumption of these antibiotics and antibiotic resistance trends seen in a U.S.-Mexico
border area hospital.
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Chapter 4: Hypotheses
The working hypotheses for this study are that there will be decreasing trends in
susceptibility over time among all antibiotic-microorganism combinations analyzed and that
there will be a positive correlation between antibiotic consumption and time among all
antibiotics analyzed. Additionally, it was hypothesized that there will be a negative correlation
between the consumption of antibiotics and the susceptibility of the microorganisms analyzed.
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Chapter 5: Methods and Materials
This study employed a retrospective analysis of antibiotic resistance and antibiotic
consumption secondary data in a small border area hospital in El Paso, Texas to determine if a
correlation existed between the two variables for the time-period of 2013-2015. An Institutional
Review Board (IRB) exemption application was submitted for this study in January of 2016 since
the study involved no human subjects and only de-identified secondary data would be utilized.
The University of Texas at El Paso (UTEP) IRB approved this study in February of 2016 and the
hospital research committee approved this study in December of 2016.
Antibiotic resistance data
Antibiotic resistance data was obtained through the hospital antibiograms, which are
compiled every six months utilizing the Clinical and Laboratory Standards Institute Analysis and
Presentation of Cumulative Antimicrobial Susceptibility Test Data; Approved Guideline (Clinical
and Laboratory Standards Institute, 2014). These antibiograms contain the aggregate percent
susceptibility (%S) for select species of bacteria for a given time-period. The antibiograms are
compiled every six months to encompass the susceptibility profiles from bacteria identified for the
period of January through June and July through December for the years 2013-2015. Only
susceptibility profiles from the first isolate of a species of bacteria per patient per reporting period
is included in the antibiograms to avoid duplicate analysis. Susceptibility profiles from bacteria
identified from diagnostic samples are included in these antibiograms only. Susceptibility profiles
from bacteria identified from samples collected for surveillance purposes are not included in the
antibiograms.

Aztreonam and the cephalosporins were excluded from analysis for ESBL

producing E. coli because these antibiotics were automatically reported as resistant if an E. coli
isolate was positive for the ESBL enzyme.
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Antibiotic consumption data
Antibiotic consumption data was obtained from hospital pharmacy billing data. Billing
data was used as a proxy for antibiotic consumption. The total amount of charges for select
antibiotics was tabulated for the period of January through June and July through December for
the years 2013-2015. The amount of charges for select antibiotics was then converted to grams
(g) or million units (MU), where applicable, based on the strength and dosage form of the antibiotic
charged. The defined daily dose (DDD) per 1000 patient days was then calculated using the World
Health Organization ATC/DDD index that can be found at https://www.whocc.no/atc_ddd_index/
and hospital census data.
Study Design
A retrospective analysis of hospital antibiotic resistance data and antibiotic consumption
data was performed by compiling the data into six month periods beginning in January of 2013
and ending in December of 2015. Analysis was performed to determine trends in antibiotic
resistance and antibiotic consumption and to determine if a correlation existed between antibiotic
consumption and antibiotic resistance trends. Five species of bacteria were chosen for this analysis
based on clinical significance and emerging resistance concerns. Only species of bacteria with
susceptibility data for ≥ 30 isolates were chosen for statistical validity. These bacterial species
included E. coli, ESBL producing E. coli, P. aeruginosa, S. aureus, and MRSA. The susceptibility
profile for these bacteria were analyzed based on the antibiotic formulary for the hospital. Only
antibiotics used to treat infections from all body sites were included in the analysis. Antibiotics
used to, primarily, treat urinary tract infections were excluded from the analysis. The fourteen
antibiotics included in the analysis were Aztreonam, Cefazolin, Cefepime, Ceftriaxone,
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Ciprofloxacin, Gentamicin, Imipenem, Piperacillin-tazobactam, Trimethoprim-sulfamethoxazole,
Levofloxacin, Oxacillin, Penicillin, Tetracycline, and Vancomycin.
Statistical Analysis
Antibiotic resistance data was compiled into six month periods beginning in January of
2013 and ending in December of 2015. Each species of bacteria was analyzed for trends in
resistance against each of the antibiotics included in the study according to the hospital’s antibiotic
formulary. The Cochran–Armitage test for trends was used to assess trends in resistance using
Microsoft Excel and XLSTAT software. Increases in resistance was documented by identifying a
decrease in susceptibility among each specific bacterial species and antibiotic combination over
time (2013-2015).

Decreases in resistance was documented by identifying an increase in

susceptibility among each specific bacterial species and antibiotic combination over time (20132015). A p-value of <0.05 was used to indicate statistical significance. Antibiotic resistance data
for S. aureus could not be assessed for the periods January-June of 2013 and July-December of
2013 since the antibiograms only included data for Methicillin Susceptible S. aureus (MSSA) and
MRSA and did not include data for all S. aureus isolates as a separate category.
Antibiotic consumption data was compiled into six month periods beginning in January of
2013 and ending in December of 2015. The quantity of antibiotics charged was converted to grams
or million units, where applicable, and then the DDD/1000 patient days was derived. Antibiotics
were assessed for trends in consumption if a trend in resistance was found when evaluating
antibiotic resistance trends among the select species of bacteria using the Cochran–Armitage test
for trends. The DDD for penicillin and trimethoprim-sulfamethoxazole could not be calculated as
the billing data did not contain the exact dosage and strength for these particular antibiotics.
Additionally, some antibiotics (Tetracycline, Oxacillin, Imipenem) were not billed for during the
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study period or for a particular period and the DDD could not be calculated. Spearman correlation
test was used to assess for trends in antibiotic consumption over time (2013-2015) due one of the
variables (time) being ordinal using Microsoft Excel and XLSTAT software. A correlation
coefficient value of 0.6 ≤ R ≤ 1 indicated a positive correlation, a correlation coefficient value of
-1 ≤ R ≤ -0.6 indicated a negative correlation, and a correlation coefficient value of R=0 or -0.6 <
R < 0.6 indicated no correlation if the p-value was statistically significant (p-value <0.05).
The correlation of antibiotic resistance and antibiotic consumption was assessed for
bacteria exhibiting a trend in resistance regardless if a trend in antibiotic consumption, for the
particular antibiotic, was identified. Spearman or Pearson correlation test was used to assess for
correlations of antibiotic resistance and antibiotic consumption over time (2013-2015) depending
on the normality of the distribution of antibiotic resistance and antibiotic consumption data using
Microsoft Excel and XLSTAT software. Normality of the data was indicated if the value for
skewness (Fisher) was between -1 and 1. A correlation coefficient value of 0.6 ≤ R ≤ 1 indicated
a positive correlation, a correlation coefficient value of -1 ≤ R ≤ -0.6 indicated a negative
correlation, and a correlation coefficient value of R=0 or -0.6 < R < 0.6 indicated no correlation if
the p-value was statistically significant (p-value <0.05).
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Chapter 6: Results
Descriptive statistics
Descriptive statistics analysis for antibiotic resistance data included the number of isolates
for the various bacterial species analyzed, the percent susceptibility (Table 1), and assessment of
normality for the susceptibility of the various bacterial species to the antibiotics of analysis.
Assessment of normality of the susceptibility data was determined after analysis of trends in
antibiotic resistance for only the bacteria-antibiotic combinations that demonstrated trends in
resistance and are referenced later in the results section.
Descriptive statistics analysis for antibiotic consumption data included the DDD/1000
patient days (Table 2) and assessment of normality for the of the various antibiotics of analysis.
Assessment of normality of the antibiotic consumption data was determined after analysis of trends
in antibiotic resistance for only the bacteria-antibiotic combinations that demonstrated trends in
resistance and are referenced later in the results section.
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Table 1: Percent Susceptibilities for the Bacterial Species Analyzed, 2013-2015
Organism/Antibiotic

% Susceptibility
Jan-Jun 2013

Jul-Dec 2013

Jan-Jun 2014

Jul-Dec 2014

Jan-Jun 2015

Jul-Dec 2015

E. coli

n=448

n=472

n=452

n=580

n=534

n=608

Aztreonam

99

100

93

93

93

90

Cefazolin

94

95

89

88

88

86

Cefepime

99

100

93

93

93

90

Ceftriaxone

99

99

93

92

93

90

Ciprofloxacin

80

81

75

74

74

74

Gentamicin

90

90

88

88

91

91

Imipenem

100

100

100

99

100

100

Piperacillin-Tazobactam

95

96

96

96

95

95

66

67

66

67

67

65

ESBL E.coli

n=30

n=43

n=32

n=42

n=41

n=59

Ciprofloxacin

0

12

3

5

2

5

Trimethoprim-sulfamethoxazole

Gentamicin

33

47

53

41

78

58

Imipenem

100

100

100

98

100

100

Piperacillin-Tazobactam

77

91

91

86

88

81

33

37

29

41

29

34

P. aeruginosa

n=66

n=105

n=107

n=95

n=89

n=131

Aztreonam

62

65

60

72

62

65

Trimethoprim-sulfamethoxazole

Cefepime

88

90

86

90

94

84

Ciprofloxacin

80

73

68

78

75

75

Gentamicin

77

84

77

86

89

85

Imipenem

91

90

87

86

92

87

Piperacillin-Tazobactam

89

87

78

92

91

82

S. aureus

NA

NA

n=306

n=254

n=320

n=260

Ciprofloxacin

NA

NA

73

78

83

78

Gentamicin

NA

NA

99

97

98

98

Levofloxacin

NA

NA

74

78

84

79

Oxacillin

NA

NA

76

73

80

74

Penicillin

NA

NA

10

15

15

16

Tetracycline

NA

NA

95

94

96

97

Vancomycin

NA

NA

100

100

100

100

MRSA

n=89

n=68

n=74

n=66

n=64

n=69

Ciprofloxacin

33

32

19

30

34

38

Gentamicin

98

99

97

91

97

94

Levofloxacin

33

32

22

30

34

28

Tretracycline
Trimethoprim-sulfamethoxazole
Vancomycin

96

97

95

94

95

97

100

100

96

97

97

99

100

100

100

100

100

100

NA= Data unavailable
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Table 2: Defined Daily Dose per 1000 Patient Days, 2013-2015
Antibiotic

DDD/1000 patient days
Jan-Jun 2013

Jul-Dec 2013

Jan-Jun 2014

Jul-Dec 2014

Jan-Jun 2015

Jul-Dec 2015

Aztreonam

1.9

5.1

1.4

2.4

1.5

1.2

Cefazolin

38.1

40.8

44.6

37.1

36.1

48.6

Cefepime

21.0

27.6

24.6

33.6

39.4

25.7

Ceftriaxone

80.6

85.7

82.5

81.7

88.9

96.3

Ciprofloxacin

27.7

17.3

19.0

21.2

14.7

14.2

Gentamicin

17.2

22.8

9.6

7.7

9.1

13.4

Imipenem

0.7

0.05

0.1

0.3

⎻

⎻

Piperacillin-Tazobactam

186

179.3

188.5

223.2

244.1

227.7

Trimethoprim-sulfamethoxazole
Levofloxacin

NA

NA

NA

NA

NA

NA

177.3

160.2

172.6

137.8

140.6

128.7

Oxacillin

⎻

⎻

⎻

⎻

⎻

⎻

Penicillin

NA

NA

NA

NA

NA

NA

Tetracycline

⎻

⎻

⎻

⎻

⎻

⎻

Vancomycin

48

96.6

79.5

58.2

71.1

61.2

No charges existed for tetracycline, oxacillin, and imipenem for the periods indicated by a dash
NA= Data unavailable. Unable to calculate due to the lack of dosage information contained in the billing data

Inferential statistics
Antibiotic resistance data was analyzed for trends in resistance over time using the
Cochran-armitage test for trends (Table 3 and Table 4). Statistically significant increases in
resistance were identified for E. coli against the following antibiotics: aztreonam (p-value
<0.0001), cefazolin (p-value <0.0001), cefepime (p-value <0.0001), ceftriaxone (p-value
<0.0001), and ciprofloxacin (p-value 0.001). A statistically significant increase in resistance for
MRSA against gentamicin was also identified (p-value 0.044). Statistically significant decreases
in resistance were identified for ESBL producing E. coli against gentamicin (p-value 0.002) and
for S. aureus against the following antibiotics: ciprofloxacin (p-value 0.023), levofloxacin (pvalue 0.018), and penicillin (p-value 0.021).
Antibiotic consumption data was converted into the DDD/1000 patient days and analyzed
by the Spearman correlation test (Table 5). Antibiotics were only analyzed for trends in
consumption if a trend in resistance was identified for a bacterial species to that particular
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antibiotic. The only trend identified was a negative correlation between time and levofloxacin
consumption for the study period (Spearman correlation R= -0.886, p-value 0.033).
The correlation of antibiotic resistance (%S) and antibiotic consumption (DDD/1000
patient days) was assessed for bacteria exhibiting a trend in resistance regardless if a trend in
antibiotic consumption, for the particular antibiotic, was identified (Table 6). Spearman or
Pearson correlation test was used to assess for correlations of antibiotic resistance and antibiotic
consumption depending on the normality of the distribution of antibiotic resistance and antibiotic
consumption data. The normality of antibiotic resistance data (%S) for E. coli to aztreonam
(skewness value 0.580), cefazolin (skewness value 0.676), cefepime (skewness value 0.580),
ceftriaxone (skewness value 0.581), ciprofloxacin (skewness value 0.951), and gentamicin
(skewness value -0.523) was normal. The normality of antibiotic resistance data (%S) for S.
aureus to ciprofloxacin (skewness value 0.00) and levofloxacin (skewness value 0.356) was also
normal. The normality of antibiotic resistance data (%S) for MRSA to gentamicin (skewness
value -1.103) was abnormal. The normality of antibiotic consumption data (DDD/1000 patient
days) for cefazolin (skewness value 0.849), cefepime (skewness value 0.819), gentamicin
(skewness value 0.948) and levofloxacin (skewness value 0.123) was normal and abnormal for
aztreonam (skewness value 2.017), ceftriaxone (skewness value 1.257), and ciprofloxacin
(skewness value 1.124). Spearman correlation was used to assess for correlations if one of the
variables (%S or DDD/1000 patient days) exhibited an abnormal distribution. Pearson
correlation was used to assess for correlations if both variables (%S and DDD/1000 patient days)
exhibited a normal distribution. No correlations were identified between any of the %S of the
bacterial species and the antibiotic consumption data (DDD/1000 patient days) analyzed.
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Table 3: Bacterial Species Exhibiting a Decrease in Susceptibility (Increase in Resistance), 2013-2015
Organism/Antibiotic

% Susceptibility (n)
Jan-Jun 2013 Jul-Dec 2013 Jan-Jun 2014 Jul-Dec 2014 Jan-Jun 2015 Jul-Dec 2015

p-value (lowertailed)

E. coli

n=448

n=472

n=452

n=580

n=534

n=608

Aztreonam

99

100

93

93

93

90

<0.0001

Cefazolin

94

95

89

88

88

86

<0.0001

Cefepime

99

100

93

93

93

90

<0.0001

Ceftriaxone

99

99

93

92

93

90

<0.0001

Ciprofloxacin

80

81

75

74

74

74

0.001

MRSA

n=89

n=68

n=74

n=66

n=64

n=69

Gentamicin

98

99

97

91

97

94

0.044

Table 4: Bacterial Species Exhibiting an Increase in Susceptibility (Decrease in Resistance), 2013-2015
Organism/Antibiotic

% Susceptibility (n)
Jan-Jun 2013 Jul-Dec 2013 Jan-Jun 2014 Jul-Dec 2014 Jan-Jun 2015 Jul-Dec 2015

p-value (uppertailed)

ESBL E. coli

n=30

n=43

n=32

n=42

n=41

n=59

Gentamicin

33

47

53

41

78

58

n=306

n=254

n=320

n=260

Ciprofloxacin

NA

NA

73

78

83

78

0.023

Levofloxacin

NA

NA

74

78

84

79

0.018

Penicillin

NA

NA

10

15

15

16

0.021

S. aureus

0.002

NA= Data unavailable

Table 5: Correlation Between Time and Antibiotic Consumption for Antibiotics where Bacterial Trends in Susceptability was Identified,
2013-2015
Antibiotic

DDD/1000 patient days
Jan-Jun 2013 Jul-Dec 2013 Jan-Jun 2014 Jul-Dec 2014 Jan-Jun 2015 Jul-Dec 2015

R

p-value

Aztreonam

1.9

5.1

1.4

2.4

1.5

1.2

-0.600

0.242

Cefazolin

38.1

40.8

44.6

37.1

36.1

48.6

0.086

0.919

Cefepime

21.0

27.6

24.6

33.6

39.4

25.7

0.543

0.297

Ceftriaxone

80.6

85.7

82.5

81.7

88.9

96.3

0.771

0.103

Ciprofloxacin

27.7

17.3

19.0

21.2

14.7

14.2

-0.771

0.103

Gentamicin

17.2

22.8

9.6

7.7

9.1

13.4

-0.543

0.297

Levofloxacin

177.3

160.2

172.6

137.8

140.6

128.7

-0.886

0.033
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Table 6: Correlation of Antibiotic Consumption and Antibiotic Resistance for Bacterial
Species Exhibiting a Trend in Susceptibility, 2013-2015
Antibiotic

E.coli

MRSA

S. aureus

R

p-value

R

p-value

R

p-value

Aztreonam

0.820

0.058

⎻

⎻

⎻

⎻

Cefazolin

-0.328

0.525

⎻

⎻

⎻

⎻

Cefepime

-0.337

0.514

⎻

⎻

⎻

⎻

Ceftriaxone

-0.471

0.356

⎻

⎻

⎻

⎻

Ciprofloxacin

0.395

0.497

⎻

⎻

-0.316

0.750

Gentamicin

0.366

0.476

0.812

0.058

⎻

⎻

Levofloxacin

⎻

⎻

⎻

⎻

-0.647

0.353

No trends in resistance were identified for the bacterial species-antibiotic combination indicated by a dash
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Chapter 7: Discussion
Antibiotic resistance due to the excessive use of antibiotics is a growing public health
threat. Geographical, cultural and other unique differences in the U.S.-Mexico border region can
contribute to antibiotic resistance trends not seen in other parts of the U.S. Antibiotic resistance
and antibiotic consumption studies in the U.S.-Mexico border region are rare, however. Without
increased antibiotic resistance and consumption surveillance data, important findings can be
missed in this unique region. The goal of this study was to increase knowledge of antibiotic
resistance and antibiotic consumption trends in the U.S.-Mexico border region. This study
identified statistically significant increases in resistance among E. coli to aztreonam, cefazolin,
cefepime, ceftriaxone, and ciprofloxacin. Additionally, a statistically significant increase in
resistance among MRSA to gentamicin was also identified for the study period. Statistically
significant decreases in resistance were identified for ESBL producing E. coli to gentamicin and
for S. aureus to ciprofloxacin, levofloxacin, and penicillin. The only trend in antibiotic
consumption identified was a negative correlation between time and levofloxacin consumption
for the study period. No correlations between any of the %S of the bacterial species and the
antibiotic consumption data (DDD/1000 patient days) analyzed were identified.
This study’s finding of increasing resistance among E.coli to ceftriaxone and
ciprofloxacin compares similar to the U.S. as a whole. Rates of resistance among E.coli to the
third-generation generation cephalosporins and fluoroquinolones have been increasing well over
the last decade. The % susceptibility of E.coli to third-generation generation cephalosporins and
fluoroquinolones has decreased from 98% in 1999 to 84% in 2014 and from 95% in 1999 to 65%
in 2014, respectively (p-value <0.0001, p-value <0.0001) (Center for Disease Dynamics
Economics & Policy, 2017). Antibiotic resistance studies on the U.S.-Mexico border are rare,

24

however, one study did identify a statistically significant increase in resistance among E.coli to
third-generation cephalosporins and fluoroquinolones in the U.S.-Mexico border (Benoit et al.,
2014). A recent study of U.S. Department of Defense hospitals identified a positive correlation
among E.coli ciprofloxacin resistance and ciprofloxacin prescription rates (Spearman correlation
R= 0.53, p-value 0.01) (Spencer, Milburn, & Chukwuma, 2016). Although this thesis study did
not find any correlation between antibiotic consumption and resistance rates for any of the
bacterial species analyzed, increases in resistance could be due to the presence of resistant genes
already circulating in the study hospital or community. Interesting findings with this thesis study
were the identification of increases in susceptibility among S.aureus to ciprofloxacin,
levofloxacillin, and penicillin. The increase in susceptibility of S.aureus to penicillin has been
found in other studies in the U.S. (Chabot, Stefan, Friderici, Schimmel, & Larioza, 2015;
Kanjilal et al., 2017). Although the correlation between penicillin consumption and penicillin
resistance in S.aureus could not be determined in this thesis study, a decrease in penicillin usage
could be related to this trend. S.aureus is highly resistant to penicillin and physicians at the
study hospital may avoid prescribing this antibiotic for this bacterial species due to this fact.
Penicillin should be considered for penicillin susceptible S.aureus as this antibiotic has several
advantages due to its narrow spectrum of activity and lack of association with CDI (Chabot et al.,
2015). Although no correlation between the %S of S.aureus to levofloxacin consumption was
identified, levofloxacin consumption did decrease at this hospital and may have contributed to
the increase in susceptibility of S.aureus to levofloxacin.
This study is subject to a few limitations. First, billing data was used as a proxy for
antibiotic consumption and may not accurately reflect actual antibiotic consumption by
individuals at this hospital. Medication administration records are preferable to pharmacy billing
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data; however, these are more difficult to access. Second, the metric chosen for antibiotic
consumption (DDD) is limited in that this metric is not appropriate for children and it can
underestimate antibiotic consumption if the actual administered dose differs from the WHO
DDD (Schechner, Temkin, Harbarth, Carmeli, & Schwaber, 2013). Third, the study period of
three years may be too small a window to identify significant trends in emerging antibiotic
resistance patterns. Resistance to antibiotics may arise shortly after the introduction of an
antibiotic or may take decades as in the case of vancomycin-resistant S.aureus (Zaman et al.,
2017). This fact highlights the importance of continuous antibiotic resistance surveillance efforts
in order to identify new antibiotic resistance patterns. There are several strengths associated with
this study. First, this study is the only study that assessed both trends in antibiotic resistance and
antibiotic consumption on the U.S.-Mexico border to determine correlations between the two
variables. Other studies lacked the antibiotic consumption component. Second, this thesis study
examined subpopulations of E.coli and S.aureus (MRSA, ESBL E.coli) to a variety of antibiotics
and not just one. This thesis study also has several implications for public and border health.
The increase in resistance of E.coli to the cephalosporins and fluoroquiolones analyzed is a
serious concern corroborated by other U.S. and U.S.-Mexico border studies. Although this study
may not be generalizable to other hospitals in the U.S.-Mexico border region, it provides preintervention data for comparison against future ASP implementation at the study hospital.
Tracking trends in resistance is an important aspect of managing antibiotic resistance at any
hospital. Local public health departments may also be interested in this data as it provides a
snapshot of antibiotic resistance patterns in this region. City-wide antibiotic resistance
surveillance could be achievable as most, if not all, hospitals produce antibiograms annually or
semi-annually.
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The Master of Public Health program at UTEP integrates five core Hispanic and border
health competencies into the coursework for this degree. These include: biostatistics,
environmental health, epidemiology, health policy and management, and social and behavioral
sciences. The integration of four of these competencies was included in this thesis study.
Biostatistics was utilized to analyze data related to antibiotic resistance and consumption in the
U.S.-Mexico border and then to make meaningful conclusions based on this analysis. The data
used for this study was epidemiological in nature and when combined with biostatistics,
important epidemiological trends in antibiotic resistance were identified in the U.S.-Mexico
border. This study also acknowledged the behavioral and cultural practices that could possibly
contribute to unique antibiotic resistance and consumption trends in the U.S.-Mexico border
region. Lastly, this study provides data that can be used in the development of health policy such
as with the implementation of ASPs at the study hospital or with the implementation of city-wide
antibiotic resistance monitoring.
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